{"id":"W3137610925","doi":"10.1016/s1470-2045(21)00005-x","title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Merck","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Interim analysis; Oncology; Internal medicine; Interim; Refractory (planetary science); Open label; Lymphoma; Hodgkin lymphoma; Clinical trial; Cancer; Immunotherapy; Materials science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004080823,0.0016739,0.003281075,0.0004219828,0.0004956966,0.001678167,0.001135984,0.001618525,0.005713834],"category_scores_gemma":[0.002674576,0.0007966677,0.002722519,0.0003906314,0.001316691,0.002067574,0.0005787378,0.004315602,0.001221026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009737032,"about_ca_system_score_gemma":0.001010517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009570558,"about_ca_topic_score_gemma":0.0019013,"domain_scores_codex":[0.9986745,0.0008176101,0.00005313235,0.0001488668,0.0000696646,0.0002362484],"domain_scores_gemma":[0.9983097,0.0007239273,0.0002910869,0.0001757238,0.00007341534,0.0004261211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9828265,0.001809257,0.0003607445,0.0002715506,0.0009948631,0.0000267037,0.00004138056,0.0005624315,0.001200566,0.00008144615,0.0004827073,0.01134189],"study_design_scores_gemma":[0.917827,0.07620116,0.002992949,0.00004526773,0.0009963618,0.00005020085,0.00004033328,0.0005995665,0.0004385711,0.00026558,0.0005191419,0.00002400568],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889289,0.004728906,0.0008013291,0.0006114053,0.0004405001,0.001194607,0.001199405,0.0001317519,0.001963198],"genre_scores_gemma":[0.9908943,0.001624555,0.001503298,0.0009718023,0.0002528113,0.00121654,0.001214872,0.00003712063,0.002284736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005713834,"threshold_uncertainty_score":0.02158171,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1578634463106528,"score_gpt":0.4562258883862628,"score_spread":0.29836244207561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}